title: Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution.
abstract: OBJECTIVE
  To investigate the efficacy of rebamipide in a rat model of colitis and restitution of intestinal epithelial cells in vitro.
  
  
  METHODS
  Acute colitis was induced with trinitrobenzene sulfonic acid (TNBS) in male Wistar rats. Rats received intrarectal rebamipide treatment daily starting on day 7 and were sacrificed on day 14 after TNBS administration. The distal colon was removed to evaluate the various parameters of inflammation. Moreover, wound healing assays were used to determine the enhanced restitution of rat intestinal epithelial (RIE) cells treated with rebamipide.
  
  
  RESULTS
  Intracolonic administration of rebamipide accelerated TNBS-induced ulcer healing. Increases in the wet weight of the colon after TNBS administration were significantly inhibited by rebamipide. The wound assay revealed that rebamipide enhanced the migration of RIE cells through phosphorylation of extracellular signal-regulated kinase (ERK) and activation of Rho kinase.
  
  
  CONCLUSIONS
  Rebamipide enema healed intestinal injury by enhancing restitution of RIE cells, via ERK activation. Rebamipide might be a novel therapeutic approach for inflammatory bowel disease.
authors: Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine 602-8566 Kyoto, Japan.
authors: Tomohisa
authors: T
authors: Takagi
authors: Yuji
authors: Y
authors: Naito
authors: Kazuhiko
authors: K
authors: Uchiyama
authors: Toshimitsu
authors: T
authors: Okuda
authors: Katsura
authors: K
authors: Mizushima
authors: Takahiro
authors: T
authors: Suzuki
authors: Osamu
authors: O
authors: Handa
authors: Takeshi
authors: T
authors: Ishikawa
authors: Nobuaki
authors: N
authors: Yagi
authors: Satoshi
authors: S
authors: Kokura
authors: Hiroshi
authors: H
authors: Ichikawa
authors: Toshikazu
authors: T
authors: Yoshikawa
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D002460:Cell Line; D003106:Colon / Q000033:anatomy & histology / Q000187:drug effects* / Q000473:pathology; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D007413:Intestinal Mucosa / Q000166:cytology / Q000187:drug effects*; D008297:Male; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D014456:Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000897:Anti-Ulcer Agents; D015363:Quinolones; C052785:rebamipide; D000409:Alanine